September 2018 – The CenterWatch Monthly : PDF
Start-up Costs Can Be an Uphill Slog in Need of Change
Frustration about clinical trial start-up costs is not unlike Sisyphus’ dilemma. A host of long-standing expense and inefficiency realities continues to create such uphill headwinds for the clinical trial sector. According to some sources, such problems even threaten the viability of the sector.
Status Quo is Not a Viable Option: A Host of Challenges Strain Clinical Trial Site Viability
Clinical trial site finances are a problem that keeps getting bigger. While there’s agreement improvements are on the horizon — and at least one sponsor is working to shake things up — there’s also a lot of frustration about the slow pace of reinvention. A host of longstanding challenges are intensifying. These issues range from sluggish payments, contract viability, preferred site status, interconnectivity and something less tangible — a lack of consideration in the relationship.
Also in this issue:
- Part 4: How to Identify Candidate Fraudulence Early in the Recruitment Cycle
- Top Considerations for Using Digital Health Devices in Clinical Trials
- Risk-based Quality Management: The New Normal
- Regulatory Update
- FDA Actions